Development of anti-cytokine therapeutics
Drug | Targeted cytokine | Biologic type | Indication | Clinical status | Company |
---|---|---|---|---|---|
Cancer | |||||
BE-8 | IL-6 | Murine mAb | B-lympho proliferative disorder; Multiple myeloma | Phase I | Diaclone |
AvastinTM (bevacizumab) | Vascular endothelial growth factor | Humanized mAb | Advanced breast and colorectal cancer | Phase III | Genentech |
Autoimmune Disorder | |||||
REMICADE® (infliximab) | TNF-α | Chimeric mAb | RA, CD; Psoriasis | Approved;Phase II/III | Johnson & Johnson/Centocor |
Enbrel® (etanercept) | TNF-α, LT-α | Receptor/Ig fusion protein | RA, JRA, Psoriatic arthritis;Psoriasis | Approved; | Immunex |
D2E7 (adalimumab) | TNF-α | Human mAb | RA | Phase III | Abbott |
HuMax-IL15 | IL-15 | Human mAb | RA | Phase I/II | Genmab A/S, Immunex |
ABX-IL-8 | IL-8 | Human mAb | Psoriasis | Phase II | Abgenix |
KineretTM (anakinra) | IL-1 receptor | Receptor antagonist | RA | Approved | Amgen |
Transplantation | |||||
Simulect® (basiliximab) | IL-2Rα | Chimeric mAb | Acute kidney transplant rejection | Approved | Novartis |
Zenapax® (daclizimab) | IL-2Rα | Humanized mAb | Acute kidney transplant rejection | Approved | Protein Design Labs/Hoffman LaRoche |
Respiratory | |||||
NuvanceTM (altrakincept) | IL-4 | Receptor/Ig fusion protein | Asthma | Phase II | Immunex |
SB240683 | IL-4 | Humanized mAb | Asthma | Phase II | Protein Design Labs/GSK |
SB240563 (mepolizumab) | IL-5 | Humanized mAb | Asthma | Phase II | GSK |
ABX-IL-8 | IL-8 | Human mAb | Chronic obstructive pulmonary disease | Phase II | Abgenix |